Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Chan, David L ^a   Pavlakis, Nick ^a   Shapiro, Jeremy ^b   Price, Timothy J ^c   Karapetis, Christos S ^d   Tebbutt, Niall C ^e   Segelov, Eva ^f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e AUSTIN HEALTH   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR; PROTEIN P21; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MOLECULAR TARGETED THERAPY; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84942889837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135599     Document Type: Review

References (40)

1. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The lancet oncology. 2013; 14(1):29-37. doi:10.1016/S1470-2045(12)70477-1 PMID: 23168366.
2. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(5):663-71. doi:10.1200/JCO.2008.20.8397 PMID: 19114683.
3. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2008; 19(7):1288-92. doi:10.1093/annonc/mdn058 PMID: 18349029.
4. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British journal of cancer. 2011; 105(1):58-64. doi:10.1038/bjc.2011.201 PMID: 21673685; PubMed Central PMCID: PMC3137415.
5. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. The lancet oncology. 2013; 14(11):1077-85. doi:10.1016/S1470-2045(13)70154-2 PMID: 24028813.
6. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(12):1539-44. doi:10.1200/JCO.2006.09.6305 PMID: 17442997.
7. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chinese journal of cancer. 2011; 30(10):682-9. doi:10.5732/cjc.011.10188 PMID: 21959045.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(1):60-5. PMID: 12506171.
9. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(16):3697-705. doi:10.1200/JCO.2005.05.112 PMID: 15738537.
10. Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, et al. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. The oncologist. 2008; 13(9):1021-9. doi:10.1634/ theoncologist.2008-0003 PMID: 18776057.
11. Masi G, L F, Salvatore L., et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III "BEBYP" trial by the Gruppo Oncologico Nord Ovest (GONO). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31 ((suppl; abstr 3615)).
12. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377(9783):2103-14. doi:10.1016/ S0140-6736(11)60613-2 PMID: 21641636; PubMed Central PMCID: PMC3159415.
13. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2015.
14. Pericay CFG, Saunders M., Thomas A., Roh J., Lopez R., et al. Phase 2 randomized, noncomparative open-label study of aflibercept and modified FOLFOX6 in the first line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 2012; 23((Suppl. 4): iv16, abstract 0024.).
15. Saltz LB, Clarke S, Diaz-Rubio E, ScheithauerW, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(12):2013-9. doi:10.1200/JCO.2007.14.9930 PMID: 18421054.
16. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The lancet oncology. 2013; 14 (8):749-59. doi:10.1016/S1470-2045(13)70163-3 PMID: 23725851; PubMed Central PMCID: PMC3699713.
17. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(19):3191-8. doi:10.1200/JCO. 2009.27.7723 PMID: 20516443.
18. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(15):1755-62. doi:10.1200/jco.2011.38.0915 PMID: 22473155.
19. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England journal of medicine. 2009; 360(14):1408-17. doi:10.1056/NEJMoa0805019 PMID: 19339720.
20. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(16):1931-8. doi: 10.1200/JCO.2012.44.8308 PMID: 23569301.
21. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(31):4697-705. doi:10.1200/JCO.2009.27.4860 PMID: 20921465.
22. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(10):1626-34. doi:10.1200/JCO.2007.14.7116 PMID: 18316791.
23. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine. 2008; 359(17):1757-65. doi:10.1056/NEJMoa0804385 PMID: 18946061.
24. Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer treatment reviews. 2012; 38(6):618-25. doi:10.1016/j.ctrv.2011.11.002 PMID: 22118887.
25. Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, et al. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PloS one. 2012; 7(11):e50925. doi:10.1371/ journal.pone.0050925 PMID: 23226426; PubMed Central PMCID: PMC3511401.
26. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. The oncologist. 2013; 18(9):1004-12. doi:10.1634/theoncologist.2013-0107 PMID: 23881988; PubMed Central PMCID: PMC3780632.
27. Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The lancet oncology. 2014; 15(6):601-11. doi:10.1016/S1470-2045(14)70105-6 PMID: 24717919
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. 2004; 350(23):2335-42. doi:10.1056/NEJMoa032691 PMID: 15175435.
29. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(28):3499-506. doi:10.1200/JCO.2012.42.8201 PMID: 22949147.
30. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(14):2311-9. doi:10.1200/JCO.2007.13.1193 PMID: 18390971.
31. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. European journal of cancer. 2015; 51 (10):1243-52. doi:10.1016/j.ejca.2015.04.007 PMID: 25937522.
32. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. New England Journal of Medicine. 2013; 369 (11):1023-34. doi:10.1056/NEJMoa1305275 PMID: 24024839
33. Van Cutsem E, Lenz H-J, Köhne C-H, Heinemann V, Tejpar S, Melezínek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Journal of Clinical Oncology. 2015; 33(7):692-700. doi:10.1200/JCO.2014.59.4812 PMID: 25605843
34. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. The lancet oncology. 2010; 11(1):38-47. doi:10.1016/ S1470-2045(09)70330-4 PMID: 19942479.
35. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - a randomized trial of the German AIO CRC study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(8):1050-8. doi:10.1200/JCO.2010.31.1936 PMID: 21300933.
36. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World journal of gastroenterology: WJG. 2010; 16(25):3133-43. PMID: 20593498; PubMed Central PMCID: PMC2896750.
37. Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, et al. Clinical impact of antiepidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer. 2012; 118 (6):1523-32. doi:10.1002/cncr.26460 PMID: 22009364.
38. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The lancet oncology. 2014; 15 (10):1065-75. doi:10.1016/S1470-2045(14)70330-4 PMID: 25088940
39. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(5s):(suppl; abstr LBA3).
40. Khattak MA, Martin H, Davidson A, Phillips M. Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. Clinical colorectal cancer. 2015. doi:10.1016/j.clcc.2014.12.011 PMID: 25666296.